A valuable additional tool in the fight against vector-borne diseases in Vietnam
HCMC, December 05th 2018, Bayer Vietnam, Environmental Science Division launch of K-Othrine Polyzone, a valuable additional tool in the fight against vector-borne diseases in Vietnam.
Overview the launch of K-Othrine Polyzone in Vietnam
Follow Mr. Le Trung Kien, Head of Experimental Chemistry Unit, National Institute of Malaria, Parasitology and Entomology (NIMPE) said in Vietnam, there were a cumulative total of 77 355 cases with 11 deaths in 2018. While the number of dengue-related deaths appears to be under control, we cannot be complacent in the fight against this menacing disease.
Vector control remains a major pillar for the control of insect-borne diseases, the majority of which are mosquito-borne. Despite significant progress in reducing the overall burden of malaria globally, the disease remains at the forefront for efforts to curb transmission further and strive towards elimination. Much of the recent reduction in the global malaria burden has been achieved through the scale-up of core vector control interventions, namely insecticide-treated netting and other materials, and indoor residual spraying (IRS) with insecticides.
Mr. Le Trung Kien presents the current state of dengue hemorrhagic fever in Vietnam and his experience using K-Othrine® Polyzone™ 62.5 SC
While remarkable progress has been seen against malaria, other mosquito-borne pathogens, in particular, arthropod-borne viruses have proven refractory to most control efforts. Dengue, for example, has not only shown strong persistence in southern Asia, but has also expanded globally into the Americas and Africa in the past four decades to become endemic. More recently, other Aedes-borne viruses (chikungunya and Zika) have emerged as important diseases with global reach. With these emergent and re-emergent vector-borne disease risks, here has never been a greater need for vector control tools than now.
Representative of Bayer Environmental Science Vietnam introduces K-Othrine® Polyzone™ 62.5 SC
Mr. Say Piau Lim – Country Division Head Environmental Science, Bayer Vietnam said: “We launched K-Othrine Polyzone, a new formulation of pyrethroid insecticide for longer lasting residually. This polymer-enhanced formulation is developed by Bayer in partnership Innovative Vector Control Consortium in UK (IVCC). In Vietnam, we partnered with National Institute of Malaria, Parasitology and Entomology (NIMPE) to conduct field trials in dengue-endemic hotspot in Nha Trang, and we had the privilege of Mr Kien Le Trung (Head of Experimental Chemistry Unit, NIMPE) to give a technical presentation on the trial results.”
K-Othrine® Polyzone™ 62.5 SC
At Bayer, our commitment to fight vector-borne disease remains integral with our 360 Vector Control approach where we provide innovative product portfolio, interdisciplinary partnerships, training and education programs as well as global advocacy.
Guests join the event launch of K-Othrine Polyzone in Vietnam
This proprietary technology, a polymer-enhanced suspension concentrate aqueous formulation that protects the active ingredient from weather, rainfall and mechanical abrasion makes it suitable for indoor residual spray as well as targeted outdoor application for mosquito control.
Key messages about K-Othrine® Polyzone™ 62.5 SC from Bayer Environmental Science Vietnam team.
“We strongly believe that the launch of K-Othrine Polyzone is an important addition to the vector control toolbox in Vietnam. Coupled with strong partnerships in the vector control network in the region, Bayer remains committed in the fight against vector-borne disease in Vietnam.” shared by Mr. Say Piau Lim.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.